Abstract
Background: Stroke remains the second commonest cause of death and leading cause of adult disability worldwide. Ischemic events account for nearly 85% of all strokes, and hemorrhages account for nearly 15%. Stroke intervention and recovery have been identified as the important factors in the functional outcome of patients with completed stroke. However, the only FDA approved treatment for ischemic strokes is tissue plasminogen activator, and no effective targeted therapy for hemorrhagic stroke exists yet.
Methods: The goal of this work is to review the brain drug delivery systems (BDDS) used for stroke intervention and recovery. Results: Many novel BDDS have been developed for the use of stroke intervention and recovery, including nanoparticles, hydrogels, fibers, liposomes, and so on, which could improve the permeability of blood-brainbarrier (BBB), short half-life, stability in vivo, and reduce adverse effects of drugs. Conclusion: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery.Keywords: Brain drug delivery, ischemic stroke, intracerebral hemorrhage, stroke intervention, stroke recovery.
Current Pharmaceutical Design
Title:Brain Drug Delivery Systems for the Stroke Intervention and Recovery
Volume: 23 Issue: 15
Author(s): Tiantian Luo, Ju Wang, Shilei Hao*, Tingwang Guo, Peng Ren, Zhongjun Cheng, Feiyan Gao, Yuhua Gong and Bochu Wang*
Affiliation:
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030,China
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030,China
Keywords: Brain drug delivery, ischemic stroke, intracerebral hemorrhage, stroke intervention, stroke recovery.
Abstract: Background: Stroke remains the second commonest cause of death and leading cause of adult disability worldwide. Ischemic events account for nearly 85% of all strokes, and hemorrhages account for nearly 15%. Stroke intervention and recovery have been identified as the important factors in the functional outcome of patients with completed stroke. However, the only FDA approved treatment for ischemic strokes is tissue plasminogen activator, and no effective targeted therapy for hemorrhagic stroke exists yet.
Methods: The goal of this work is to review the brain drug delivery systems (BDDS) used for stroke intervention and recovery. Results: Many novel BDDS have been developed for the use of stroke intervention and recovery, including nanoparticles, hydrogels, fibers, liposomes, and so on, which could improve the permeability of blood-brainbarrier (BBB), short half-life, stability in vivo, and reduce adverse effects of drugs. Conclusion: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery.Export Options
About this article
Cite this article as:
Luo Tiantian, Wang Ju, Hao Shilei*, Guo Tingwang, Ren Peng, Cheng Zhongjun, Gao Feiyan, Gong Yuhua and Wang Bochu*, Brain Drug Delivery Systems for the Stroke Intervention and Recovery, Current Pharmaceutical Design 2017; 23 (15) . https://dx.doi.org/10.2174/1381612822666161025155058
DOI https://dx.doi.org/10.2174/1381612822666161025155058 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design N-Butyl Cyanoacrylate Embolization of a Peripheral Pulmonary Artery Aneurysm in a Patient with Patent Ductus Arteriosus
Current Cardiology Reviews Mechano-chemo-biological Computational Models for Arteries in Health, Disease and Healing: From Tissue Remodelling to Drug-eluting Devices
Current Pharmaceutical Design The Association of Connective Tissue Disorders with Cervical Artery Dissections
Current Molecular Medicine Late-Onset Glycogen Storage Disease Type 2
Current Molecular Medicine Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy Encephalopathy: A Vicious Cascade Following Forebrain Ischemia and Hypoxia
Central Nervous System Agents in Medicinal Chemistry Intracoronary Brachytherapy - Clinical State and Pathophysiological Considerations
Current Pharmaceutical Design Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art
Current Medicinal Chemistry <i>In silico</i> Approach for Exploring the Role of AT1R Polymorphism on its Function, Structure and Drug Interactions
Current Computer-Aided Drug Design Neonatal Hypertension: An Underdiagnosed Condition, A Review Article
Current Hypertension Reviews Antimicrobial Treatment to Impair Expansion of Abdominal Aortic Aneurysm (AAA): A Systematic Review of the Clinical Evidence
Current Vascular Pharmacology Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) The Clinical Utility and Assessment of Renal Biomarkers in Acute Kidney Injury After Abdominal Endovascular Aneurysm Repair. A Systematic Review
Current Pharmaceutical Design Progression and Disruption of Advanced Atherosclerotic Plaques in Murine Models
Current Drug Targets Endovascular vs. Open Repair of Abdominal Aortic Aneurysms and Renal Function
Current Vascular Pharmacology A Survey on Medical Image Segmentation
Current Medical Imaging